DiaMedica Therapeutics (DMAC) Competitors $6.96 +0.10 (+1.46%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$6.78 -0.19 (-2.66%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. AVDL, JANX, EVO, RCUS, STOK, LENZ, SNDX, SION, XERS, and TSHAShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Avadel Pharmaceuticals (AVDL), Janux Therapeutics (JANX), Evotec (EVO), Arcus Biosciences (RCUS), Stoke Therapeutics (STOK), LENZ Therapeutics (LENZ), Syndax Pharmaceuticals (SNDX), Sionna Therapeutics (SION), Xeris Biopharma (XERS), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Its Competitors Avadel Pharmaceuticals Janux Therapeutics Evotec Arcus Biosciences Stoke Therapeutics LENZ Therapeutics Syndax Pharmaceuticals Sionna Therapeutics Xeris Biopharma Taysha Gene Therapies Avadel Pharmaceuticals (NASDAQ:AVDL) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Do analysts recommend AVDL or DMAC? Avadel Pharmaceuticals currently has a consensus price target of $20.86, suggesting a potential upside of 46.78%. DiaMedica Therapeutics has a consensus price target of $12.33, suggesting a potential upside of 77.20%. Given DiaMedica Therapeutics' higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.70DiaMedica Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to AVDL or DMAC? In the previous week, Avadel Pharmaceuticals had 7 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 9 mentions for Avadel Pharmaceuticals and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.95 beat Avadel Pharmaceuticals' score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in AVDL or DMAC? 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 5.2% of Avadel Pharmaceuticals shares are held by company insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, AVDL or DMAC? Avadel Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Which has stronger earnings & valuation, AVDL or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$221.08M6.24-$48.83M-$0.03-473.67DiaMedica TherapeuticsN/AN/A-$24.44M-$0.69-10.09 Is AVDL or DMAC more profitable? DiaMedica Therapeutics has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -1.32%. Avadel Pharmaceuticals' return on equity of -3.73% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-1.32% -3.73% -1.73% DiaMedica Therapeutics N/A -78.99%-69.94% SummaryAvadel Pharmaceuticals beats DiaMedica Therapeutics on 10 of the 16 factors compared between the two stocks. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$354.59M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-10.0921.5785.5627.61Price / SalesN/A271.42535.65201.06Price / CashN/A47.1237.9261.55Price / Book7.3310.1413.036.76Net Income-$24.44M-$52.31M$3.30B$275.88M7 Day Performance-0.57%5.14%4.35%2.81%1 Month Performance-3.47%14.68%9.50%9.24%1 Year Performance54.67%30.98%85.16%35.42% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics2.1967 of 5 stars$6.96+1.5%$12.33+77.2%+49.7%$354.59MN/A-10.0920Analyst ForecastAVDLAvadel Pharmaceuticals2.554 of 5 stars$14.53-3.2%$20.86+43.5%+12.2%$1.46B$169.12M-484.3370Positive NewsAnalyst DowngradeAnalyst RevisionJANXJanux Therapeutics1.8119 of 5 stars$22.76-5.2%$78.31+244.1%-46.1%$1.44B$10.59M-12.6430Analyst ForecastEVOEvotec1.6079 of 5 stars$3.99-0.5%$5.40+35.3%+22.1%$1.42B$862.40M0.004,827News CoverageAnalyst ForecastRCUSArcus Biosciences1.9027 of 5 stars$14.54+8.9%$21.14+45.4%-13.8%$1.42B$258M-4.59500News CoverageAnalyst ForecastInsider TradeHigh Trading VolumeSTOKStoke Therapeutics3.2472 of 5 stars$26.81+4.9%$25.57-4.6%+148.4%$1.40B$36.56M31.54100News CoverageAnalyst ForecastInsider TradeLENZLENZ Therapeutics0.6633 of 5 stars$46.11-5.4%$49.60+7.6%+99.1%$1.39BN/A-24.27110Positive NewsAnalyst ForecastSNDXSyndax Pharmaceuticals3.7556 of 5 stars$16.40+5.1%$39.22+139.2%-10.2%$1.34B$23.68M-4.22110Analyst ForecastAnalyst RevisionSIONSionna Therapeutics2.7931 of 5 stars$29.25-2.5%$38.00+29.9%N/A$1.32BN/A0.0035Analyst ForecastInsider TradeXERSXeris Biopharma2.8577 of 5 stars$8.13-0.9%$7.08-12.9%+178.9%$1.32B$203.07M-38.71290News CoveragePositive NewsAnalyst ForecastTSHATaysha Gene Therapies2.5199 of 5 stars$4.42-7.1%$9.00+103.6%+151.7%$1.30B$8.33M-13.00180Analyst ForecastGap Up Related Companies and Tools Related Companies Avadel Pharmaceuticals Alternatives Janux Therapeutics Alternatives Evotec Alternatives Arcus Biosciences Alternatives Stoke Therapeutics Alternatives LENZ Therapeutics Alternatives Syndax Pharmaceuticals Alternatives Sionna Therapeutics Alternatives Xeris Biopharma Alternatives Taysha Gene Therapies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
